Council of Canadians
The Parliamentary Budget Officer (PBO) revealed that new intellectual property provisions in the Canada-United States-Mexico Agreement would cost Canadians as much as $169 million more per year for pharmaceutical drugs
In a letter to Congress, the groups demand that the pact’s giveaways to Big Pharma that would keep medicines unaffordable be removed before the pact is sent to Congress.
NAFTA 2.0 would effectively tie the US Congress’ hands in the struggle against rising drug prices.
The Intellectual Property Chapter of the revised NAFTA, rebranded by the Trump Administration USMCA, includes provisions that threaten to undermine critical efforts towards affordable health care and medicine.
Multinational corporations are suing countries for using generic versions of life saving medicines.
Don’t trade our lives away
Civil society organisations, patient groups and health activists have been concerned about intellectual property provisions being discussed in RCEP which undermine access to medicines and affordable treatment for patients
Canada’s negotiators extended data protection on biologics without knowing impact on prices.
European Pharmaceutical Manufacturer
Patients may need to wait an extra five or 10 years to access generic medicines, which could raise healthcare costs by as $100 billion over the next five years, according to the latest CPhI annual report
Experts are fuming, saying USMCA will hamper Canada’s innovation economy and hike costs to the health care system over patented drugs.
The 10-year span is more than what had existed before but the biopharma industry has long argued for the same 12-year exclusivity that exists for biologics within the US market.